Next generation of immune checkpoint inhibitors and beyondJulian A. Marin‐Acevedo, Yanyan Lou|Journal of Hematology & Oncology|2021Cited by 537
Targeted therapy in advanced non-small cell lung cancer: current advances and future trendsUmair Majeed, Yanyan Lou|Journal of Hematology & Oncology|2021Cited by 271
Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trialCharu Aggarwal, Nehal J. Lakhani, Alex A. Adjei et al.|Journal for ImmunoTherapy of Cancer|2022Cited by 140
Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective studyMaliazurina B. Saad, Jia Wu, Lingzhi Hong et al.|The Lancet Digital Health|2023Cited by 108
A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer.Elena Garralda, Gerald S. Falchook, Ammar Sukari et al.|Journal of Clinical Oncology|2021Cited by 46